Histone deacetylases exert class-specific roles in conditioning the brain and heart against acute ischemic injury

Frontiers in Neurology

Volumn 6, Issue JUN, 2015, Pages

  Aune, Sverre E ^a   Herr, Daniel J ^a   Kutz, Craig J ^a   Menick, Donald R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Enzymatic crosstalk; Histone deacetylase inhibitors; Ischemia reperfusion injury; Postconditioning; Posttranslational modification; Preconditioning; Reperfusion injury salvage kinase; Stroke

Indexed keywords

BIM PROTEIN; ENTINOSTAT; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN C JUN; PROTEIN KINASE B; TRICHOSTATIN A; VALPROIC ACID;

ACETYLATION; BRAIN ISCHEMIA; CATALYSIS; CEREBROVASCULAR ACCIDENT; CHROMATIN IMMUNOPRECIPITATION; DEACETYLATION; GENETIC HETEROGENEITY; HEART MUSCLE ISCHEMIA; HISTONE ACETYLATION; HUMAN; METHYLATION; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; SHORT SURVEY; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84936949828     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00145     Document Type: Short Survey

References (105)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update. Circulation (2014) 131:e29-322. doi:10.1161/cir.0000000000000152
2. Schweizer S, Meisel A, Marschenz S. Epigenetic mechanisms in cerebral ischemia. J Cereb Blood Flow Metab (2013) 33:1335-46. doi:10.1038/jcbfm.2013.93
3. Dirnagl U, Becker K, Meisel A. Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol (2009) 8(4):398-412. doi:10.1016/S1474-4422(09)70054-7
4. Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci (2006) 7(6):437-48. doi:10.1038/nrn1927
5. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (2006) 367(9524):1747-57. doi:10.1016/S0140-6736(06)68770-9
6. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 124(1):30-9. doi:10.1172/JCI69738
7. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene (2007) 26:5310-8. doi:10.1038/sj.onc.1210599
8. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, et al. "Ischemic tolerance" phenomenon found in the brain. Brain Res (1990) 528(1):21-4. doi:10.1016/0006-8993(90)90189-I
9. Dezfulian C, Garrett M, Gonzalez NR. Clinical application of preconditioning and postconditioning to achieve neuroprotection. Transl. Stroke Res (2013) 4(1):19-24. doi:10.1007/s12975-012-0224-3
10. Moskowitz MA, Lo EH, Iadecola C. The science of stroke-mechanisms in search of treatments. Neuron (2010) 67(2):181-98. doi:10.1016/j.neuron.2010.07.002
11. Ginsberg MD. Neuroprotection for Ischemic stroke: past, present and future. Neuropharmacology (2008) 55(3):363-89. doi:10.1016/j.neuropharm.2007.12.007
12. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci (2003) 26(5):248-54. doi:10.1016/S0166-2236(03)00071-7
13. Yuan J. Neuroprotective strategies targeting apoptotic and necrotic cell death for stroke. Apoptosis (2009) 14(4):469-77. doi:10.1007/s10495-008-0304-8
14. Bodalia A, Li H, Jackson MF. Loss of endoplasmic reticulum Ca2+ homeostasis: contribution to neuronal cell death during cerebral ischemia. Acta Pharmacol Sin (2013) 34(1):49-59. doi:10.1038/aps.2012.139
15. Sugawara T, Noshita N, Lewén A, Gasche Y, Ferrand-Drake M, Fujimura M, et al. Overexpression of copper/zinc superoxide dismutase in transgenic rats protects vulnerable neurons against ischemic damage by blocking the mitochondrial pathway of caspase activation. J Neurosci (2002) 22(1):209-17.
16. Gao Y, Signore AP, Yin W, Cao G, Yin X-M, Sun F, et al. Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway. J Cereb Blood Flow Metab (2005) 25(6):694-712. doi:10.1038/sj.jcbfm.9600062
17. Sharp FR, Kinouchi H, Koistinaho J, Chan PH, Sagar SM. HSP70 heat shock gene regulation during ischemia. Stroke (1993) 24(12 Suppl):I72-5.
18. Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, Chavez JC. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci (2007) 27(23):6320-32. doi:10.1523/JNEUROSCI.0449-07.2007
19. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao T-P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell (2003) 115(6):727-38. doi:10.1016/S0092-8674(03)00939-5
20. Porter K, Medford HM, McIntosh CM, Marsh SA. Cardioprotection requires flipping the "posttranslational modification" switch. Life Sci (2012) 90(3-4):89-98. doi:10.1016/j.lfs.2011.10.026
21. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res (2006) 70:240-53. doi:10.1016/j.cardiores.2006.01.017
22. Hashiguchi A, Yano S, Morioka M, Hamada J, Ushio Y, Takeuchi Y, et al. Up-regulation of endothelial nitric oxide synthase via phosphatidylinositol 3-kinase pathway contributes to ischemic tolerance in the CA1 subfield of gerbil hippocampus. J Cereb Blood Flow Metab (2004) 24(3):271-9. doi:10.1097/01.WCB.0000110539.96047.FC
23. Zhao H. Ischemic postconditioning as a novel avenue to protect against brain injury after stroke. J Cereb Blood Flow Metab (2009) 29(5):873-85. doi:10.1038/jcbfm.2009.13
24. Lai EW, Toledo-Pereyra LH, Walsh J, Lopez-Neblina F, Anaya-Prado R. The role of MAP kinases in trauma and ischemia-reperfusion. J Invest Surg (2004) 17(1):45-53. doi:10.1080/08941930490269646
25. Gershey EL, Vidali G, Allfrey VG. Chemical studies of histone acetylation. the occurrence of epsilon-N-acetyllysine in the f2a1 histone. J Biol Chem (1968) 243(19):5018-22.
26. Rundlett SE, Carmen AA, Kobayashi R, Bavykin S, Turner BM, Grunstein M. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci U S A (1996) 93(25):14503-8. doi:10.1073/pnas.93.25.14503
27. Taunton J, Hassiq CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science (1996) 272(5260):408-11. doi:10.1126/science.272.5260.408
28. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol (2011) 95(3):373-95. doi:10.1016/j.pneurobio.2011.09.001
29. Baltan S, Bachleda A, Morrison RS, Murphy SP. Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia. Transl Stroke Res (2011) 2(3):411-23. doi:10.1007/s12975-011-0087-z
30. Chen YT, Zang XF, Pan J, Zhu XL, Chen F, Chen ZB, et al. Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection. Clin Exp Pharmacol Physiol (2012) 39(9):751-8. doi:10.1111/j.1440-1681.2012.05729.x
31. Yang X-J, Grégoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol (2005) 25(8):2873-84. doi:10.1128/MCB.25.8.2873-2884.2005
32. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell (2008) 31(4):449-61. doi:10.1016/j.molcel.2008.07.002
33. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene (2005) 363:15-23. doi:10.1016/j.gene.2005.09.010
34. Thompson JW, Dave KR, Young JI, Perez-Pinzon MA. Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance. Neurotherapeutics (2013) 10(4):789-97. doi:10.1007/s13311-013-0202-9
35. Bardai FH, Price V, Zaayman M, Wang L, D'Mello SR. Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. J Biol Chem (2012) 287(42):35444-53. doi:10.1074/jbc.M112.394544
36. Fan J, Alsarraf O, Dahrouj M, Platt KA, Chou CJ, Rice CJ, et al. Inhibition of HDAC2 protects the retina from ischemic injury. Invest Ophthalmol Vis Sci (2013) 54(6):4072-80. doi:10.1167/iovs.12-11529
37. Gibson CL, Murphy SP. Benefits of histone deacetylase inhibitors for acute brain injury-a systematic review of animal studies. J Neurochem (2010) 115(4):806-13. doi:10.1111/j.1471-4159.2010.06993.x
38. Langley B, Brochier C, Rivieccio MA. Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke (2009) 40:2899-905. doi:10.1161/STROKEAHA.108.540229
39. Kabukas N, Ay I, Aysun S, Söylemezoglu F, Ozcan A, Celasun B. Protective effects of valproic acid against hypoxic-ischemic brain injury in neonatal rats. J Child Neurol (2005) 20(7):582-7. doi:10.1177/08830738050200070801
40. Wang Z, Tsai LK, Munasinghe J, Leng Y, Fessler EB, Chibane F, et al. Chronic valproate treatment enhances post-ischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. Stroke (2012) 43(9):2430-6. doi:10.1161/STROKEAHA.112.652545
41. Liu XS, Chopp M, Kassis H, Jia LF, Hozeska-Solgot A, Zhang RL, et al. Valproic acid increases white matter repair and neurogenesis after stroke. Neuroscience (2012) 220:313-21. doi:10.1016/j.neuroscience.2012.06.012
42. Kim HJ, Leeds P, Chuang MW. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem (2009) 110(4):1226-40. doi:10.1111/j.1471-4159.2009.06212.x
43. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke-multiple mechanisms of action. J Pharmacol Exp Ther (2007) 321(3):892-901. doi:10.1124/jpet.107.120188
44. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem (2004) 89(6):1358-67. doi:10.1111/j.1471-4159.2004.02406.x
45. Biermann J, Grieshaber P, Goebel U, Martin G, Thanos S, Di Giovanni S, et al. Valproic-acid mediated neuroprotection and regeneration in injured retinal ganglion cells. Invest Opthalmol Vis Sci (2010) 51(1):526-34. doi:10.1167/iovs.09-3903
46. Zhang Z, Tong N, Gong Y, Qiu Q, Yin L, Lv X, et al. Valproate protects the retina from endoplasmic reticulum stress-induced apoptosis after ischemia-reperfusion injury. Neurosci Lett (2011) 504(2):88-92. doi:10.1016/j.neulet.2011.09.003
47. Marinova Z, Ren M, Wendland JR, Leng Y, Liang MH, Yasuda S, et al. Valproic acid induces functional heat-shock protein 70 via class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem (2009) 111(4):976-87. doi:10.1111/j.1471-4159.2009.06385.x
48. Endres M, Meisel A, Biniszkiewicz D, Namura S, Prass K, Ruscher K, et al. DNA methyltransferase contributes to delayed ischemic brain injury. J Neurosci (2000) 20(9):3175-81.
49. Yildirim F, Gertz K, Kronenberg G, Harms C, Fink KB, Meisel A, et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol (2008) 210(2):531-42. doi:10.1016/j.expneurol.2007.11.031
50. Wang B, Zhu X, Kim Y, Li J, Huang S, Saleem S, et al. Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage. Free Radic Biol Med (2012) 52(5):928-36. doi:10.1016/j.freeradbiomed.2011.12.006
51. Crosson CE, Mani SK, Husain S, Alsarraf O, Menick DR. Inhibition of histone deacetylase protects the retina from ischemic injury. Invest Ophthalmol Vis Sci (2010) 51(7):3639-45. doi:10.1167/iovs.09-4538
52. Alsarraf O, Fan J, Dahrouj M, Chou CJ, Menick DR, Crosson CE. Acetylation: a lysine modification with neuroprotective effects in ischemic retinal degeneration. Exp Eye Res (2014) 127:124-31. doi:10.1016/j.exer.2014.07.012
53. Langley B, D'Annibale MA, Suh K, Ayoub I, Tolhurst A, Bastan B, et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-dependent neuroprotection. J Neurosci (2008) 28(1):163-76. doi:10.1523/JNEUROSCI.3200-07.2008
54. Gonzalez-Zulueta M, Feldman AB, Klesse LJ, Kalb RG, Dillman JF, Parada LF, et al. Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning. Proc Natl Acad Sci U S A (2000) 97(1):436-41. doi:10.1073/pnas.97.1.436
55. Shim J, Lee H, Park J, Kim H, Choi EJ. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature (1996) 381(6585):804-6. doi:10.1038/381804a0
56. Qi X, Hosoi T, Okuma Y, Kaneko M, Nomura Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol Pharmacol (2004) 66:899-908. doi:10.1124/mol.104.001339
57. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol (2007) 25(1):84-90. doi:10.1038/nbt1272
58. Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol (2006) 70(6):1876-84. doi:10.1124/mol.106.027912
59. Lanzillota A, Pignataro G, Branca C, Cuomo O, Sarnico I, Benarese M, et al. Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. Neurobiol Dis (2013) 49:177-89. doi:10.1016/j.nbd.2012.08.018
60. Bellenguez C, Bevan S, Gschwendtner A, Spence CCA, Burgess AI, Pirinen M, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 44(3):328-33. doi:10.1038/ng.1081
61. Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. HDAC4 inhibits cell cycle progression and protects neurons from cell death. Dev Neurobiol (2008) 68(8):1076-92. doi:10.1002/dneu.20637
62. Ma C, D'Mello SR. Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism. J Biol Chem (2011) 286(6):4819-28. doi:10.1074/jbc.M110.146860
63. Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science (2009) 323(5911):256-9. doi:10.1126/science.1166226
64. He M, Zhang B, Wei X, Wang Z, Fan B, Du P, et al. HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury. J Cell Mol Med (2013) 17(4):531-42. doi:10.1111/jcmm.12040
65. Cho Y, Sloutsky R, Naegle KM, Cavalli V. Injury-induced HDAC5 nuclear export is essential for axon regeneration. Cell (2013) 155(4):894-908. doi:10.1016/j.cell.2013.10.004
66. Schlumm F, Mauceri D, Freitag HE, Bading H. Nuclear calcium signaling regulates nuclear export of a subset of class IIa histone deacetylases following synaptic activity. J Biol Chem (2013) 288(12):8074-84. doi:10.1074/jbc.M112.432773
67. Soriano FX, Chawla S, Skehel P, Hardingham GE. SMRT-mediated co-shuttling enables export of class IIa HDACs independent of their CaM kinase phosphorylation sites. J Neurochem (2013) 124(1):26-35. doi:10.1111/jnc.12058
68. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature (2000) 408(6808):106-11. doi:10.1038/35040593
69. Bardai FH, D'Mello SR. Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. J Neurosci (2011) 31(5):1746-51. doi:10.1523/JNEUROSCI.5704-10.2011
70. Marinova Z, Leng Y, Leeds P, Chuang DM. Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology (2011) 60(7-8):1109-15. doi:10.1016/j.neuropharm.2010.09.022
71. Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis (2013) 34(6):1196-207. doi:10.1093/carcin/bgt033
72. Jenuwein TL, Allis CD. Translating the histone code. Science (2001) 293(5532):1074-80. doi:10.1126/science.1063127
73. McKinsey TA. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol (2012) 52:303-16. doi:10.1146/annurev-pharmtox-010611-134712
74. Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J (2008) 22:3549-60. doi:10.1096/fj.08-108548
75. Dana A, Skarli M, Papakrivopoulou J, Yellon DM. Adenosine A(1) receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism. Circ Res (2000) 86(9):989-97. doi:10.1161/01.RES.86.9.989
76. Martindale JJ, Wall JA, Martinez-Longoria DM, Aryal P, Rockman HA, Guo Y, et al. Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. J Biol Chem (2005) 280(1):669-76. doi:10.1074/jbc.M406690200
77. Zhao TC, Taher MM, Valerie KC, Kukreja RC. p38 triggers late preconditioning elicited by anisomycin in heart: involvement of NF-kappaB and iNOS. Circ Res (2001) 89(10):915-22. doi:10.1161/hh2201.099452
78. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res (2004) 61(3):448-60. doi:10.1016/j.cardiores.2003.09.024
79. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, akt, and endothelial nitric oxide synthase phosphorylation. Circulation (2002) 105(12):1497-502. doi:10.1161/01.CIR.0000012529.00367.0F
80. Jonassen AK, Sack MN, Mjøs OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via akt and p70s6 kinase cell-survival signaling. Circ Res (2001) 89(12):1191-8. doi:10.1161/hh2401.101385
81. Matsui T, Li L, del Monte F, Fukui Y, Franke TF, Hajjar RJ, et al. Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation (1999) 100(23):2373-9. doi:10.1161/01.CIR.100.23.2373
82. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation (2000) 101(6):660-7. doi:10.1161/01.CIR.101.6.660
83. Vondriska TM, Zhang J, Song C, Tang X-L, Cao X, Baines CP, et al. Protein kinase C e-Src modules direct signal transduction in nitric oxide-induced cardioprotection: complex formation as a means for cardioprotective signaling. Circ Res (2001) 88:1306-13. doi:10.1161/hh1201.092994
84. Párrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. J Biol Chem (1997) 272(1):154-61. doi:10.1074/jbc.272.1.154
85. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal (2011) 14(5):893-907. doi:10.1089/ars.2010.3360
86. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-Kinase-Akt pathway. Circ Res (2004) 95(3):230-2. doi:10.1161/01.RES.0000138303.76488.fe
87. Zhao TC, Zhang LX, Cheng G, Liu JT. gp-91 mediates histone deacetylase inhbition-induced cardioprotection. Biochim Biophys Acta (2010) 1803(7):872-80. doi:10.1016/j.bbamcr.2010.04.007
88. Zhao TC, Cheng G, Zhang LX, Tseng YT, Padbury JF. Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc Res (2007) 76(3):473-81. doi:10.1016/j.cardiores.2007.08.010
89. Zhao TC, Du J, Zhuang S, Liu P, Zhang LX. HDAC inhibition elicits myocardial protective effect through modulation of MKK3/Akt-1. PLoS One (2013) 8(6):e65474. doi:10.1371/journal.pone.0065474
90. Zhang L, Qin X, Zhao Y, Fast L, Zhuang S, Liu P, et al. Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis. J Pharmacol Exp Ther (2012) 341(1):285-93. doi:10.1124/jpet.111.189910
91. Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, Han H, et al. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res (1999) 84(9):1095-109. doi:10.1161/01.RES.84.9.1095
92. Maulik N, Sato M, Price BD, Das DK. An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett (1998) 429(3):365-9. doi:10.1016/S0014-5793(98)00632-2
93. Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer (2009) 125(12):2863-70. doi:10.1002/ijc.24748
94. Li RC, Ping P, Zhang J, Wead WB, Cao X, Gao J, et al. PKCepsilon modulates NF-kappaB and AP-1 via mitogen-activated protein kinases in adult rabbit cardiomyocytes. Am J Physiol Heart Circ Physiol (2000) 279(4):H1679-89.
95. Zhang LX, Zhao Y, Cheng G, Guo TL, Chin YE, Liu PY, Zhao TC. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. Am J Physiol Heart Circ Physiol (2010) 298(6):H2154-63. doi:10.1152/ajpheart.01015.2009
96. Zhang Y, Yu G, Wang D, Hu Y, Lei W. ERK1/2 activation plays important roles in the opposite effects of trichostatin A in non-cancer and cancer cells. Toxicon (2011) 57(6):932-7. doi:10.1016/j.toxicon.2011.03.008
97. Lei WW, Zhang KH, Pan XC, Wang DM, Hu Y, Yang YN, et al. Histone deacetylase 1 and 2 differentially regulate apoptosis by opposing effects on extracellular signal-regulated kinase 1/2. Cell Death Dis (2010) 1:e44. doi:10.1038/cddis.2010.21
98. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction ("stunned myocardium"). J Am Coll Cardiol (1988) 12(1):239-49. doi:10.1016/0735-1097(88)90381-6
99. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature (2002) 419(6904):316-21. doi:10.1038/nature01036
100. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science (2013) 339(6116):211-4. doi:10.1126/science.1227166
101. Aune SE, Herr DJ, Mani SK, Menick DR. Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion. J Mol Cell Cardiol (2014) 72:138-45. doi:10.1016/j.yjmcc.2014.03.005
102. Calnan DR, Brunet A. The FoxO code. Oncogene (2008) 27(16):2276-88. doi:10.1038/onc.2008.21
103. Mihaylova MM, Vasquez DS, Ravnskjaer K, Denechaud P-D, Yu RT, Alvarez JG, et al. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homoestasis. Cell (2011) 145(4):607-21. doi:10.1016/j.cell.2011.03.043
104. Yan J. Interplay between HDAC6 and its interacting partners: essential roles in the aggresome-autophagy pathway and neurodegenerative diseases. DNA Cell Biol (2014) 33(9):567-80. doi:10.1089/dna.2013.2300
105. McLendon PM, Ferguson BS, Osinska H, Bhuiyan MS, James J, McKinsey TA, et al. Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Proc Natl Acad Sci U S A (2014) 111(48):E5178-86. doi:10.1073/pnas.1415589111